177 related articles for article (PubMed ID: 9470839)
1. Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG).
Davidson A; Gowing R; Lowis S; Newell D; Lewis I; Dicks-Mireaux C; Pinkerton CR
Eur J Cancer; 1997 Oct; 33(11):1816-22. PubMed ID: 9470839
[TBL] [Abstract][Full Text] [Related]
2. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
3. Ten-day schedule oral etoposide therapy in advanced childhood malignancies.
Schiavetti A; Varrasso G; Maurizi P; Cappelli C; Clerico A; Properzi E; Castello MA
J Pediatr Hematol Oncol; 2000; 22(2):119-24. PubMed ID: 10779024
[TBL] [Abstract][Full Text] [Related]
4. 21-day schedule oral etoposide in children--a feasibility study.
Davidson A; Lewis I; Pearson AD; Stevens MC; Pinkerton CR
Eur J Cancer; 1993; 29A(16):2223-5. PubMed ID: 8110489
[TBL] [Abstract][Full Text] [Related]
5. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pharmacokinetic study of fractionated doses of oral etoposide in pediatric patients with advanced malignancies.
Gregianin LJ; Brunetto AL; Di Leone L; Costa TD; Santos PP; Schwartsmann G
Med Sci Monit; 2002 Sep; 8(9):PI70-7. PubMed ID: 12218955
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy.
Schwartsmann G; Sprinz E; Kromfield M; Kalakun L; Sander E; Prolla G; Di Leone L; Gerhardt L; Mans DR
J Clin Oncol; 1997 May; 15(5):2118-24. PubMed ID: 9164226
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer.
Millward MJ; Newell DR; Yuen K; Matthews JP; Balmanno K; Charlton CJ; Gumbrell L; Lind MJ; Chapman F; Proctor M
Cancer Chemother Pharmacol; 1995; 37(1-2):161-7. PubMed ID: 7497587
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors.
Needle MN; Molloy PT; Geyer JR; Herman-Liu A; Belasco JB; Goldwein JW; Sutton L; Phillips PC
Med Pediatr Oncol; 1997 Jul; 29(1):28-32. PubMed ID: 9142202
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of oral etoposide in children with refractory solid tumors.
Mathew P; Ribeiro RC; Sonnichsen D; Relling M; Pratt C; Mahmoud H; Bowman L; Meyer W; Avery L; Crist W
J Clin Oncol; 1994 Jul; 12(7):1452-7. PubMed ID: 8021737
[TBL] [Abstract][Full Text] [Related]
12. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.
Sprinz E; Caldas AP; Mans DR; Cancela A; DiLeone L; Dalla Costa T; Schwartsmann G
Am J Clin Oncol; 2001 Apr; 24(2):177-84. PubMed ID: 11319295
[TBL] [Abstract][Full Text] [Related]
13. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetic aspects of oral administration of etoposide].
Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
[TBL] [Abstract][Full Text] [Related]
15. Oral etoposide for recurrent/progressive sarcomas of childhood.
Kebudi R; Görgün O; Ayan I
Pediatr Blood Cancer; 2004 Apr; 42(4):320-4. PubMed ID: 14966827
[TBL] [Abstract][Full Text] [Related]
16. Response of recurrent medulloblastoma to low-dose oral etoposide.
Ashley DM; Meier L; Kerby T; Zalduondo FM; Friedman HS; Gajjar A; Kun L; Duffner PK; Smith S; Longee D
J Clin Oncol; 1996 Jun; 14(6):1922-7. PubMed ID: 8656261
[TBL] [Abstract][Full Text] [Related]
17. Etoposide in relapsed or refractory Wilms' tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.
Pein F; Pinkerton R; Tournade MF; Brunat-Mentigny M; Levitt G; Margueritte G; Rubie H; Sommelet D; Thyss A; Zücker JM
J Clin Oncol; 1993 Aug; 11(8):1478-81. PubMed ID: 8393095
[TBL] [Abstract][Full Text] [Related]
18. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule.
Perdaems N; Bachaud JM; Rouzaud P; Murris-Espin M; Hermant C; Mihura J; Lochon I; Houin G; Canal P; Chatelut E
Eur J Clin Pharmacol; 1998; 54(9-10):677-83. PubMed ID: 9923567
[TBL] [Abstract][Full Text] [Related]
19. Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Rose PG; Blessing JA; Buller RE; Mannel RS; Webster KD
Gynecol Oncol; 2003 May; 89(2):267-70. PubMed ID: 12713990
[TBL] [Abstract][Full Text] [Related]
20. Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: a phase II window study.
Mantadakis E; Herrera L; Leavey PJ; Bash RO; Winick NJ; Kamen BA
J Clin Oncol; 2000 Jul; 18(13):2576-81. PubMed ID: 10893289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]